Molar characterization and analytical UPLC method development of matrix impurity, disregards impurity, specified impurity associated undetectable impurity of laboratory drug Isatin


Molar characterization and analytical UPLC method development of matrix impurity, disregards impurity, specified impurity associated undetectable impurity of laboratory drug Isatin


Rahul Hajare

Post Doc Fellow (Batch 2013-2015) Indian Council of Medical Research, New Delhi


Journal of Pharmaceutical Research and Reviews

This is out line work on the process development for the impurity detection of Isatin from synthetic occurring and several new methods have been developed during the pursuit of this research. The article traces the evolution of various approaches and provides a comparison for overall efficiency. UPLC method has been developed and validated for simultaneous estimation of matrix impurity, disregards impurity; specified impurity associated undetectable impurity in pure synthetic formulations. Separation was carried out using column Hypersil ODS C18 (250 mm x 4.6mm x 5μm particle size) in isocratic mode using mobile phase composition pH 6.0 ammonium acetate Buffer: Acetonitrile (68:32)v/v and UV detection at 310 nm. The impurities were eluted at a flow rate of 1.0 mL/ min. The average retention times for matrix impurity, disregards impurity, specified impurity associated undetectable impurity were 2.86 and 3.67 min, 4.54 min respectively. The method was validated according to the ICH guidelines.


Keywords: Matrix impurity, disregards impurity, specified impurity associated undetectable impurity, UPLC, ICH guidelines, process development.


Free Full-text PDF


How to cite this article:
Rahul Hajare. Molar characterization and analytical UPLC method development of matrix impurity, disregards impurity, specified impurity associated undetectable impurity of laboratory drug Isatin. Journal of Pharmaceutical Research and Reviews, 2018; 2:19.


References:

1. Rahul Hajare, Smita Kulkarni, Madhuri Thakar and Ramesh Paranjape. Technology development and design of novel 1, 3, 5-tri substituted-1h-indole-2, 3-dione hiv-1 inhibitors with displays strategic nanomolar cytotoxicity, 2016; 5(6): 391-397.
2. Keitel S. (2006 Sep 27) Impurity Profiles in Active Pharmaceutical Ingredients.EU / Swissmedic GMP Workshop Beijing University.
3. Josephs JL, Sanders M, Shipkova P. (2007 Feb 25) Detection and Characterization of Pharmaceutical Metabolites, Degradants and Impurities by the Application of MS / MS Software Algorithms; Technical Program.